This was CUO 23 – Photos & Videos

Live Stream
ENP_1682
ENP_1683
ENP_1746
ENP_1752
ENP_1764
ENP_1766
ENP_1780
ENP_1786
ENP_1798
ENP_1849
ENP_1851
ENP_1859
ENP_1868
ENP_1869
ENP_1886
ENP_1899
ENP_1904
ENP_1969
ENP_2001
ENP_2007
ENP_2043
ENP_2048
ENP_2054
ENP_2078
ENP_2107
ENP_2123
ENP_2161
ENP_2171
ENP_2189
ENP_2219
ENP_2239
ENP_2254
ENP_2264
ENP_2282
ENP_2286
ENP_2303
ENP_2315
ENP_2327
ENP_2378
ENP_2363
IMG_4360
IMG_4366
IMG_4370
IMG_4373
IMG_20230414_150809
IMG_20230414_151228
IMG_20230414_154832
IMG_20230414_154837
IMG_20230414_155044
IMG_20230414_155511
IMG_20230414_155540
IMG_20230414_161531
IMG_20230414_170324
IMG_20230414_180605

CUO 23 - The Video with interviews!

1 video found
CUO 23 - The Video with interviews!
16views

Videos

22 videos found
Can we make NMIBC treatment better tolerated and cheaper, B. Pradere, FR
Can we make NMIBC treatment better tolerated and cheaper, B. Pradere, FR
Can we treat beyond guidelines, M. Schmidinger, AUT
Can we treat beyond guidelines, M. Schmidinger, AUT
Circulating tumor DNA for biomarker dectection in patients with CRPC – ready for prime time, T. Bauernhofer, AUT
Circulating tumor DNA for biomarker dectection in patients with CRPC – ready for prime time, T. Bauernhofer, AUT
Enbloc for NMIBC - Where we stand now, D. Enikeev, RU
Enbloc for NMIBC – Where we stand now, D. Enikeev, RU
Essentials of pheochromocytoma and adrenocortocal carcinoma, M. Remzi, AUT
Essentials of pheochromocytoma and adrenocortocal carcinoma, M. Remzi, AUT
How to best use current drugs/ treatment sequencing and combinations for metastatic castration resistant prostate cancer, G. Kramer, AUT
How to best use current drugs/ treatment sequencing and combinations for metastatic castration resistant prostate cancer, G. Kramer, AUT
HPV vaccination – a gender neutral cancer prevention strategy, E. Joura, AUT
HPV vaccination – a gender neutral cancer prevention strategy, E. Joura, AUT
Intensifiing treatments for mHSPC, I. Heidegger, AUT
Intensifiing treatments for mHSPC, I. Heidegger, AUT
Is there a role for triplet therapy in the first-line setting of mRCC, M. Schmidinger, AT
Is there a role for triplet therapy in the first-line setting of mRCC, M. Schmidinger, AT
Management of clinically node positive prostate cancer, J. Bektic, AUT
Management of clinically node positive prostate cancer, J. Bektic, AUT
MicroRNAs as diagnostic bio- markers in testicular cancer, M. Pichler, AUT
MicroRNAs as diagnostic bio- markers in testicular cancer, M. Pichler, AUT
Next generation therapies in NMIBC, F.Soria,IT
Next generation therapies in NMIBC, F.Soria,IT
Open surgical aspects of different urinary diversions/ pros & cons, S. Ahyai, AUT
Open surgical aspects of different urinary diversions/ pros & cons, S. Ahyai, AUT
Patient reported outcomes and perspectives in cancer surgery and therapy, M. Leitsmann, AUT
Patient reported outcomes and perspectives in cancer surgery and therapy, M. Leitsmann, AUT
Patient selection for adjuvant therapy in RCC, D. Niedersüß, AUT
Patient selection for adjuvant therapy in RCC, D. Niedersüß, AUT
Prostate cancer risk, screening and management in patients with germline BRCA1_2 mutations, P. Rajwa, PL
Prostate cancer risk, screening and management in patients with germline BRCA1_2 mutations, P. Rajwa, PL
Recent Developments in Bladder Pathology, A. Oszwald, AT
Recent Developments in Bladder Pathology, A. Oszwald, AT
Keynote Lecture, To know cancer is to defeat cancer/ lessons from precision medicine, W. Berger, AUT
Keynote Lecture, To know cancer is to defeat cancer/ lessons from precision medicine, W. Berger, AUT
Bladder preservation after neo-adjuvant chemotherapy/ possible today, M. Moschini, IT
Bladder preservation after neo-adjuvant chemotherapy/ possible today, M. Moschini, IT
Cytoreduction in mRCC/ who, how, when? H. Fajkovic, AUT
Cytoreduction in mRCC/ who, how, when? H. Fajkovic, AUT
Sequencing systemic therapies and looking to the horizon for metastatic urothelial carcinoma, C. Mir, ESP
Sequencing systemic therapies and looking to the horizon for metastatic urothelial carcinoma, C. Mir, ESP
Welcome
Welcome

Partner

Principal Partner

Gold Partner

Sponsorenlogo Olympus

Silver Partner

Bronze Partner

Sponsorenlogo Myriad
Sponsorenlogo Sandoz

Pop-Up Partner

Special Partner

(c) 2023 CUO | Impressum & Privacy Policy

Scroll to Top